Table of Contents Author Guidelines Submit a Manuscript
International Journal of Dentistry
Volume 2014, Article ID 471035, 9 pages
http://dx.doi.org/10.1155/2014/471035
Review Article

Bisphosphonate Associated Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment

1Department Oral and Maxillofacial Surgery, The Sahlgrenska Academy, University of Gothenburg, P.O. Box 450, 405 30 Gothenburg, Sweden
2Maxillofacial Unit, Linköping University Hospital, 581 85 Linköping, Sweden

Received 6 May 2014; Accepted 18 July 2014; Published 1 September 2014

Academic Editor: Giuliano Ascani

Copyright © 2014 Lars Rasmusson and Jahan Abtahi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Marx, “Pamidronate Aredia and zoledronate induced avascular necrosis of the jaws: a growing epidemic,” Journal of Oral and Maxillofacial Surgery, vol. 61, no. 9, pp. 1115–1117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S.-J. Qui, G. Gibson, K. Lundin-Cannon, and M. Schaffler, Osteocyte Aptosis after Acute Matrix Injury in Compact Bone, The Orthopaedic Research Society, San Francisco, Calif, USA, 1997.
  3. R. E. Coleman, “Future direction in the treatment and prevention of bone metastases,” American Journal of Clinical Oncology, vol. 25, pp. 2–8, 2002. View at Google Scholar
  4. I. Holen and R. E. Coleman, “Bisphosphonates as treatment of bone metastases,” Current Pharmaceutical Design, vol. 16, no. 11, pp. 1262–1271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. I. Im, S. A. Qureshi, J. Kenney, H. E. Rubash, and A. S. Shanbhag, “Osteoblast proliferation and maturation by bisphosphonates,” Biomaterials, vol. 25, no. 18, pp. 4105–4115, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. C. Cremers, G. Pillai, and S. E. Papapoulos, “Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis,” Clinical Pharmacokinetics, vol. 44, no. 6, pp. 551–570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. E. R. van Beek, C. W. G. M. Löwik, F. H. Ebetino, and S. E. Papapoulos, “Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships,” Bone, vol. 23, no. 5, pp. 437–442, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. R. G. G. Russell, Z. Xia, J. E. Dunford et al., “Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy,” Annals of the New York Academy of Sciences, vol. 1117, pp. 209–257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. G. H. Nancollas, R. Tang, R. J. Phipps et al., “Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite,” Bone, vol. 38, no. 5, pp. 617–627, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. G. G. Russell and M. J. Rogers, “Bisphosphonates: from the laboratory to the clinic and back again,” Bone, vol. 25, no. 1, pp. 97–106, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. B. J. Gertz, S. D. Holland, W. F. Kline, B. K. Matuszewski, and A. G. Porras, “Clinical pharmacology of alendronate sodium,” Osteoporosis International, vol. 3, no. 3, pp. 13–16, 1993. View at Google Scholar · View at Scopus
  12. P. T. Daley-Yates, D. J. Dodwell, M. Pongchaidecha, R. E. Coleman, and A. Howell, “The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases,” Calcified Tissue International, vol. 49, no. 6, pp. 433–435, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. J. H. Lin, I. Chen, F. A. DeLuna, and M. Hichens, “Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 267, no. 2, pp. 670–675, 1993. View at Google Scholar · View at Scopus
  14. J. H. Lin, I. W.. Chen, and F. A. deLuna, “On the absorption of alendronate in rats,” Journal of Pharmaceutical Sciences, vol. 83, no. 12, pp. 1741–1746, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. J. H. Lin, “Bisphosphonates: a review of their pharmacokinetic properties,” Bone, vol. 18, no. 2, pp. 75–85, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. W. R. Michael, W. R. King, and J. M. Wakim, “Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey,” Toxicology and Applied Pharmacology, vol. 21, no. 4, pp. 503–515, 1972. View at Publisher · View at Google Scholar · View at Scopus
  17. G. A. Rodan and H. A. Fleisch, “Bisphosphonates: mechanisms of action,” Journal of Clinical Investigation, vol. 97, no. 12, pp. 2692–2696, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Sato, W. Grasser, N. Endo et al., “Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure,” The Journal of Clinical Investigation, vol. 88, no. 6, pp. 2095–2105, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Colucci, V. Minielli, G. Zambonin et al., “Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces,” Calcified Tissue International, vol. 63, no. 3, pp. 230–235, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. D. E. Hughes, K. R. Wright, H. L. Uy et al., “Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo,” Journal of Bone and Mineral Research, vol. 10, no. 10, pp. 1478–1487, 1995. View at Google Scholar · View at Scopus
  21. P. David, H. Nguyen, A. Barbier, and R. Baron, “The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPase,” Journal of Bone and Mineral Research, vol. 11, no. 10, pp. 1498–1507, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Felix, R. G. Russell, and H. Fleisch, “The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes,” Biochimica et Biophysica Acta, vol. 429, no. 2, pp. 429–438, 1976. View at Publisher · View at Google Scholar · View at Scopus
  23. J. C. Frith, J. Mönkkönen, G. M. Blackburn, R. G. G. Russell, and M. J. Rogers, “Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro,” Journal of Bone and Mineral Research, vol. 12, no. 9, pp. 1358–1367, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers, “Molecular mechanisms of action of bisphosphonates: current status,” Clinical Cancer Research, vol. 15, pp. 6222–6230, 2006. View at Google Scholar
  25. S. P. Luckman, D. E. Hughes, F. P. Coxon, R. G. G. Russell, and M. J. Rogers, “Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras,” Journal of Bone and Mineral Research, vol. 13, no. 4, pp. 581–589, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. P. S. Mackie, J. L. Fisher, H. Zhou, and P. F. M. Choong, “Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line,” British Journal of Cancer, vol. 84, no. 7, pp. 951–958, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Viereck, G. Emons, V. Lauck et al., “Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts,” Biochemical and Biophysical Research Communications, vol. 291, no. 3, pp. 680–686, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Reddy, T. W. Weatherford III, C. A. Smith, B. D. West, M. K. Jeffcoat, and T. M. Jacks, “Alendronate treatment of naturally-occurring periodontitis in beagle dogs,” Journal of Periodontology, vol. 66, no. 3, pp. 211–217, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Weinreb, H. Quartuccio, J. G. Seedor et al., “Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys.,” Journal of Periodontal Research, vol. 29, no. 1, pp. 35–40, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Yaffe, M. Iztkovich, Y. Earon, I. Alt, R. Lilov, and I. Binderman, “Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats,” Journal of Periodontology, vol. 68, no. 9, pp. 884–889, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Wermelin, P. Aspenberg, P. Linderbäck, and P. Tengvall, “Bisphosphonate coating on titanium screws increases mechanical fixation in rat tibia after two weeks,” Journal of Biomedical Materials Research A, vol. 86, no. 1, pp. 220–227, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Yoshinari, Y. Oda, T. Inoue, K. Matsuzaka, and M. Shimono, “Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants,” Biomaterials, vol. 23, no. 14, pp. 2879–2885, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Peter, O. Gauthier, S. Laïb et al., “Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats,” Journal of Biomedical Materials Research, vol. 76, no. 1, pp. 133–143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Roshan-Ghias, J. Arnoldi, P. Procter, and D. P. Pioletti, “In vivo assessment of local effects after application of bone screws delivering bisphosphonates into a compromised cancellous bone site,” Clinical Biomechanics, vol. 26, no. 10, pp. 1039–1043, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. V. A. Stadelmann, O. Gauthier, A. Terrier, J.-M. Bouler, and D. P. Pioletti, “Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study,” European Cells and Materials, vol. 16, pp. 10–16, 2008. View at Google Scholar · View at Scopus
  36. G. Friedl, R. Radl, C. Stihsen, P. Rehak, R. Aigner, and R. Windhager, “The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty: a randomized, double-blind, controlled trial,” Journal of Bone and Joint Surgery, vol. 91, no. 2, pp. 274–281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Wilkinson, A. C. Eagleton, I. Stockley, N. F. A. Peel, A. J. Hamer, and R. Eastell, “Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial,” Journal of Orthopaedic Research, vol. 23, no. 1, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Hilding, L. Ryd, S. Toksvig-Larsen, and P. Aspenberg, “Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients,” Acta Orthopaedica Scandinavica, vol. 71, no. 6, pp. 553–557, 2000. View at Google Scholar · View at Scopus
  39. A. R. Pradeep, M. Kumari, N. S. Rao, and S. B. Naik, “1% alendronate gel as local drug delivery in the treatment of class II furcation defects: a randomized controlled clinical trial,” Journal of Periodontology, vol. 84, no. 3, pp. 307–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Sharma and A. R. Pradeep, “Clinical efficacy of 1% Alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial,” Journal of Periodontology, vol. 83, no. 1, pp. 11–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Shar and A. R. Pradeep, “Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial,” Journal of Periodontology, vol. 83, no. 1, pp. 19–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Abtahi, P. Tengvall, and P. Aspenberg, “A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants,” Bone, vol. 50, no. 5, pp. 1148–1151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Zuffetti, T. Testori, M. Capelli, M. C. Rossi, and M. del Fabbro, “The topical administration of bisphosphonates in implant surgery: a randomized split-mouth prospective study with a follow-up up to 5 years,” Clinical Implant Dentistry and Related Research, 2013. View at Publisher · View at Google Scholar
  44. A. E. Miles, “Phosphorus necrosis of the jaw: “phossy jaw”,” British Dental Journal, vol. 133, no. 5, pp. 203–206, 1972. View at Publisher · View at Google Scholar · View at Scopus
  45. M. L. Myers and J. D. McGlothlin, “Matchmakers' “phossy jaw” eradicated,” The American Industrial Hygiene Association Journal, vol. 57, no. 4, pp. 330–332, 1996. View at Google Scholar · View at Scopus
  46. M. A. Vance, “Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis,” Clinical Toxicology, vol. 45, no. 7, pp. 753–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Reuther, T. Schuster, U. Mende, and A. C. Kübler, “Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients: a report of a thirty year retrospective review,” International Journal of Oral and Maxillofacial Surgery, vol. 32, no. 3, pp. 289–295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. R. E. Marx, Y. Sawatari, M. Fortin, and V. Broumand, “Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment,” Journal of Oral and Maxillofacial Surgery, vol. 63, no. 11, pp. 1567–1575, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. S. L. Ruggiero, B. Mehrotra, T. J. Rosenberg, and S. L. Engroff, “Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases,” Journal of Oral and Maxillofacial Surgery, vol. 62, no. 5, pp. 527–534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. E. P. Wang, L. B. Kaban, G. J. Strewler, N. Raje, and M. J. Troulis, “Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 7, pp. 1328–1331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Santini, B. Vincenzi, G. Avvisati et al., “Pamidronate induces modifications of circulating angiogenetic factors in cancer patients,” Clinical Cancer Research, vol. 8, no. 5, pp. 1080–1084, 2002. View at Google Scholar · View at Scopus
  52. P. Aspenberg, “Osteonecrosis of the jaw: what do bisphosphonates do?” Expert Opinion on Drug Safety, vol. 5, no. 6, pp. 743–745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg, “Case 9–2008—a 65-year-old woman with a nonhealing ulcer of the jaw,” The New England Journal of Medicine, vol. 358, no. 12, pp. 1214–1291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. K. H. Taylor, L. S. Middlefell, and K. D. Mizen, “Osteonecrosis of the jaws induced by anti-RANK ligand therapy,” British Journal of Oral and Maxillofacial Surgery, vol. 48, no. 3, pp. 221–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. B. Woo, J. W. Hellstein, and J. R. Kalmar, “Systematic review: bisphosphonates and osteonecrosis of the jaws,” Annals of Internal Medicine, vol. 144, no. 10, pp. 753–756, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. P. López-Jornet, F. Camacho-Alonso, A. Martínez-Canovas, F. Molina-Miano, F. Gómez-García, and V. Vicente-Ortega, “Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 69, no. 10, pp. 2488–2493, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. P. K. Palaska, V. Cartsos, and A. I. Zavras, “Bisphosphonates and time to osteonecrosis development,” Oncologist, vol. 14, no. 11, pp. 1154–1166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. I. M. Twiss, R. de Water, J. Den Hartigh et al., “Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport,” Journal of Pharmaceutical Sciences, vol. 83, no. 5, pp. 699–703, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. I. M. Twiss, O. Pas, W. Ramp-Koopmanschap, J. Den Hartigh, and P. Vermeij, “The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium,” Journal of Bone and Mineral Research, vol. 14, no. 5, pp. 784–791, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. J. L. Wallace, M. Dicay, W. McKnight, S. Bastaki, and M. A. Blank, “N-bisphosphonates cause gastric epithelial injury independent of effect on the microcirculation,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 12, pp. 1675–1682, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Suri, J. Mönkkönen, M. Taskinen et al., “Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity,” Bone, vol. 29, no. 4, pp. 336–343, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Giraudo, M. Inoue, and D. Hanahan, “An amino-bisphosphonate targets MMP-9—expressing macrophages and angiogenesis to impair cervical carcinogenesis,” The Journal of Clinical Investigation, vol. 114, no. 5, pp. 623–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. A. A. Reszka, J. Halasy-Nagy, and G. A. Rodan, “Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation,” Molecular Pharmacology, vol. 59, no. 2, pp. 193–202, 2001. View at Google Scholar · View at Scopus
  64. I. R. Reid, M. J. Bolland, and A. B. Grey, “Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?” Bone, vol. 41, no. 3, pp. 318–320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Abtahi, F. Agholme, O. Sandberg, and P. Aspenberg, “Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone,” Journal of Oral Pathology & Medicine, vol. 41, no. 6, pp. 494–499, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Kahn, G. Sandor, E. Dore et al., “Bisphosphonate associated osteonecrosis of the jaw,” The Journal of Rheumatology, vol. 36, pp. 478–490, 2009. View at Publisher · View at Google Scholar
  67. J. Abtahi, Bisphosphonates and implants in the jaw bone [M.S. thesis], University of Linkoping, Linkoping, Sweden, 2013.
  68. V. Fusco, A. Loidoris, G. Colella, P. Vescovi, and G. Campisi, “Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment,” Breast, vol. 19, no. 5, pp. 432–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Vescovi, G. Campisi, V. Fusco et al., “Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study,” Oral Oncology, vol. 47, no. 3, pp. 191–194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Mavrokokki, A. Cheng, B. Stein, and A. Goss, “Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 3, pp. 415–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. J. P. Bilezikian, “Osteonecrosis of the jaw—do bisphosphonates pose a risk?” The New England Journal of Medicine, vol. 355, no. 22, pp. 2278–2281, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. “Statement by Merck & Company: Incorporated: Regarding Fosamax (alendronate sodium) and rare cases of osteonecrosis of the jaw,” Product News, 2008, http://www.mercknewsroom.com.
  73. D. Felsenberg, B. Hoffmeister, and M. Amling, “Kiefernekrosen nach hoch dosierter bisphosphonattherapie,” Deutsches Arzteblatt, vol. 103, article 3078, 2006. View at Google Scholar
  74. P. Sambrook, I. Olver, and A. Goss, “Bisphosphonates and osteonecrosis of the jaw,” Australian Family Physician, vol. 35, no. 10, pp. 801–803, 2006. View at Google Scholar · View at Scopus
  75. J. Abtahi, F. Agholme, and P. Aspenberg, “Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model,” International Journal of Oral and Maxillofacial Surgery, vol. 42, no. 5, pp. 632–636, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Barasch, J. Cunha-Cruz, F. A. Curro et al., “Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN,” Journal of Dental Research, vol. 90, no. 4, pp. 439–444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Bamias, E. Kastritis, C. Bamia et al., “Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8580–8587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Madrid and M. Sanz, “What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review,” Clinical Oral Implants Research, vol. 20, no. 4, pp. 87–95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Koka, N. M. S. Babu, and A. Norell, “Survival of dental implants in post-menopausal bisphosphonate users,” Journal of Prosthodontic Research, vol. 54, no. 3, pp. 108–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Lemound, A. Eckardt, H. Kokemüller et al., “Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap,” Clinical Oral Investigations, vol. 16, no. 4, pp. 1143–1152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Vescovi, E. Merigo, M. Meleti et al., “Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw,” International Journal of Dentistry, vol. 2014, Article ID 107690, 8 pages, 2014. View at Publisher · View at Google Scholar
  82. J. J. Freiberger, “Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, supplement, pp. 96–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Vescovi, E. Merigo, M. Manfredi et al., “Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases,” Photomedicine and Laser Surgery, vol. 26, no. 1, pp. 37–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Scoletta, P. G. Arduino, L. Reggio, P. Dalmasso, and M. Mozzati, “Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study,” Photomedicine and Laser Surgery, vol. 28, no. 2, pp. 179–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. U. Romeo, A. Galanakis, C. Marias et al., “Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results,” Photomedicine and Laser Surgery, vol. 29, no. 7, pp. 447–452, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. E. R. Carlson and J. D. Basile, “The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, pp. 85–95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Mücke, J. Koschinski, H. Deppe et al., “Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 907–913, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Seth, N. D. Futran, D. S. Alam, and P. D. Knott, “Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws,” Laryngoscope, vol. 120, no. 11, pp. 2165–2171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. O. Filleul, E. Crompot, and S. Saussez, “Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 8, pp. 1117–1124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. S. L. Ruggiero, J. Fantasia, and E. Carlson, “Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 102, no. 4, pp. 433–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Holzinger, R. Seemann, C. Klug et al., “Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs),” Oral Oncology, vol. 49, no. 1, pp. 66–70, 2013. View at Publisher · View at Google Scholar · View at Scopus